US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
GSK's Arexvy is a vaccine approved to protect older adults from ...
WEB3 days ago · GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for RSV, a common respiratory virus that can lead to serious negative ...
FDA approves first vaccine for RSV, a moment six decades in the
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
New data for AREXVY, GSK’s RSV vaccine, show potential to help …
WEBOct 25, 2023 · GSK plc (LSE/NYSE: GSK) today announced positive preliminary results from its phase III trial [NCT05590403] evaluating the immune response and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50 to 59, including those at increased risk of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) du...
GSK announces AREXVY, its respiratory syncytial virus (RSV) …
WEBAug 17, 2023 · AREXVY is indicated for the prevention of RSV-lower respiratory tract disease (LRTD) in individuals aged 60 years and older. Under the Inflation Reduction Act, patients with Medicare Part D will pay no out-of-pocket expenses.
What is Arexvy? US approves first vaccine for RSV after ... - Sky News
WEBMay 4, 2023 · On Wednesday the Food and Drug Administration (FDA) approved the use of Arexvy in the country. The vaccine is said to protect older adults against the respiratory virus.
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
WEBJun 10, 2024 · Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world. Arexvy had an exceptional launch and generated £1.2 billion in sales in 2023.
RSV Vaccine Arexvy Approved for Adults Aged 50 to 59 Years at …
WEBJun 10, 2024 · The Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract...
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US …
WEBFeb 6, 2024 · AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is currently approved in the US in adults aged 60 and over for the prevention of lower respiratory tract disease (LRTD) caused by...
Skip to content